Trubion Pharmaceuticals, the Seattle-based developer of treatments for autoimmune diseases, said today it has hired Scott Stromatt as senior vice president and chief medical officer. Stromatt previously oversaw clinical and regulatory affairs at Seattle-based Cell Therapeutics until he resigned in April. He will replace Daniel Burge, who is leaving the company in late August for “personal reasons,” the company said. Burge, 46, a veteran of Amgen and Immunex, joined Trubion in 2004.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
